Peptide LibraryThymosin Alpha-1 dosage in published studies and labels
These are the doses used for Thymosin Alpha-1 in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Thymosin alpha-1 has substantial human dosing evidence, converging on 1.6 mg subcutaneously. Published randomised trials used 1.6 mg twice weekly for 8 weeks in an outpatient prevention setting, and 1.6 mg every 12 hours for 7 days followed by 1.6 mg daily for a further 7 days in critical illness. It is marketed as thymalfasin in a number of countries but has no current FDA labelling in the United States.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 1.6 mg per dose; frequency varies by indication |
| Route | Subcutaneous |
| Frequency | Twice weekly in outpatient trials; every 12 hours in acute critical-illness protocols |
| Duration studied | 7–14 days in critical illness; 8 weeks in the prevention trial |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Severe acute necrotising pancreatitis trial (2022)Clinical trial · Randomised placebo-controlled trial | Patients with predicted severe acute necrotising pancreatitis | 1.6 mg every 12 hours for 7 days, then 1.6 mg once daily for 7 days | Subcutaneous | Every 12 hours, then once daily | 14 days total | Immune enhancement and infection | Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial. Intensive Care Med. 2022. |
| COVID-19 prevention pilot trial (2023)Clinical trial · Randomised controlled pilot trial | Randomised participants (n=194) | 1.6 mg | Subcutaneous | Twice weekly | 8 weeks | Infection and morbidity | A pilot trial of Thymalfasin (Ta1) to prevent COVID-19 infection and morbidities. Int Immunopharmacol. 2023. |
| NCT02867267 — phase 3, sepsis, completedClinical trial · Phase 3 randomised trial, completed, no results posted | Patients with sepsis (n=1106) | Per trial protocol | Subcutaneous | — | — | Efficacy and safety in sepsis | NCT02867267 — The Efficacy and Safety of Ta1 for Sepsis |
| NCT05086614 — phase 3, adjuvant after hepatocellular carcinoma resectionClinical trial · Phase 3 trial, recruiting | Patients after radical resection of high-risk hepatocellular carcinoma (n=2500) | Per trial protocol | Subcutaneous | — | — | Recurrence-free survival | NCT05086614 — Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Hepatocellular Carcinoma |
Where sources disagree
- The 1.6 mg dose is consistent across trials, but the frequency is not: twice weekly for outpatient immune support versus every 12 hours in acute critical illness. Quoting "1.6 mg" without the interval and the indication conveys almost nothing about the regimen studied.
- Almost all trial evidence is in hospitalised or seriously ill populations — sepsis, necrotising pancreatitis, hepatitis, cancer adjuvant therapy. Thymosin alpha-1 is sold for general immune support in healthy people, a setting with no comparable trial evidence.
- DailyMed lists no current FDA-labelled product. Approval as thymalfasin in other countries does not create a US approved dose.